Non-Proliferative Diabetic Retinopathy Market Insights Highlight Segment Expansion And Market Leadership

The landscape of non-proliferative diabetic retinopathy is set for substantial advancement over the coming years. With increasing awareness, technological progress, and evolving treatment options, this market is anticipated to grow notably. Below, we explore the market's projected valuation, key players, emerging trends, and detailed segmentation to provide a comprehensive understanding of this vital medical field.

Projected Market Value and Growth Outlook for Non-Proliferative Diabetic Retinopathy
The non-proliferative diabetic retinopathy market is expected to experience significant growth, reaching a valuation of $3.98 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 6.8% during the forecast period. The market's upward trajectory is driven by a rising incidence of diabetic retinopathy, greater use of anti-VEGF and steroid-based therapies, the proliferation of ophthalmology clinics and specialized centers, advancements in retinal imaging technologies, and enhanced patient education promoting early diagnosis. Key trends shaping this market include increasing adoption of anti-VEGF treatments, more frequent use of intraocular steroid injections, the growing application of advanced laser surgical techniques, expanded use of vitrectomy procedures, and the integration of artificial intelligence-powered retinal imaging and diagnostic tools.

The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.83 billion in 2025 to $3.06 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to high prevalence of diabetes, limited awareness of retinal complications, reliance on conventional laser treatments, low adoption of intravitreal injections, insufficient screening infrastructure.

Download a free sample of the non-proliferative diabetic retinopathy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Commanding the Non-Proliferative Diabetic Retinopathy Market
A number of prominent corporations hold significant influence in the non-proliferative diabetic retinopathy sector. These include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., and Kowa Company Ltd.
An important development occurred in March 2024 when Sandoz, a Switzerland-based provider of generic and biosimilar medicines, acquired the ophthalmology division of Coherus BioSciences Inc. This acquisition, valued at $170 million, included the CIMERLI (ranibizumab-eqrn) product line. Through this strategic move, Sandoz aims to strengthen its presence in the U.S. ophthalmology and biosimilar markets by broadening its range of therapies targeting retinal diseases such as non-proliferative diabetic retinopathy. Prior to the acquisition, Coherus BioSciences, a U.S.-based biopharmaceutical firm, managed the commercialization of the CIMERLI biosimilar for retinal conditions.

Clinical Trials and Innovations Driving Future Market Trends
The non-proliferative diabetic retinopathy market is seeing a strong push toward the development of advanced clinical solutions. Leading companies are concentrating on Phase 3 registrational trials aimed at validating therapeutic efficacy, building robust clinical evidence, and gaining regulatory approvals for new treatments. These trials are critical as they involve the formal enrollment and randomization of patients into pivotal late-stage studies necessary for market authorization.
For example, in November 2025, Ocular Therapeutix, a U.S.-based biopharmaceutical company focusing on retinal disease therapies, announced the randomization of the first patient in its HELIOS-3 Phase 3 registrational trial. This study evaluates AXPAXLI (OTX-TKI), an investigational bioresorbable intravitreal hydrogel that delivers axitinib, a tyrosine kinase inhibitor with anti-angiogenic properties. Designed to provide sustained treatment with fewer injections, AXPAXLI represents a potentially transformative therapy for NPDR. The HELIOS-3 trial, alongside HELIOS-2, uses a novel endpoint based on a two-step or greater improvement in the Diabetic Retinopathy Severity Score (DRSS) and includes participants with non-center-involved diabetic macular edema (non-CI-DME), positioning this treatment as a promising option for long-lasting NPDR management.

View the full non-proliferative diabetic retinopathy market report:
https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Detailed Segment Analysis of the Non-Proliferative Diabetic Retinopathy Market
The non-proliferative diabetic retinopathy market is categorized in this report according to several key segments:
1) Treatment Types: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy
2) Disease Severity Levels: Mild NPDR, Moderate NPDR, and Severe NPDR
3) End-Users: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Other Users
Further subsegments provide granular insights:
- For Anti-VEGF Therapy, products include Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), and Pegaptanib (Macugen).
- Intraocular Steroid Injections encompass Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), and Fluocinolone Acetonide Implant (Iluvien).
- Laser Surgery covers Focal Laser Photocoagulation and Panretinal Photocoagulation.
- Vitrectomy procedures include Pars Plana Vitrectomy (PPV), Membrane Peeling Vitrectomy, and Phaco-Vitrectomy, which combines cataract and vitrectomy surgery.
This detailed segmentation helps stakeholders understand treatment preferences and healthcare settings where NPDR therapies are delivered.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.